Lucira Health (Lucira Health) Interest Expense : $-2.0 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Lucira Health Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lucira Health's interest expense for the three months ended in Sep. 2022 was $ -0.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lucira Health's Operating Income for the three months ended in Sep. 2022 was $ -126.3 Mil. Lucira Health's Interest Expense for the three months ended in Sep. 2022 was $ -0.9 Mil. Lucira Health did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lucira Health Interest Expense Historical Data

The historical data trend for Lucira Health's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health Interest Expense Chart

Lucira Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Interest Expense

-0.19

-0.09

-0.05

Lucira Health Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Expense	Get a 7-Day Free Trial									-	0.28	-0.54	-0.83	-0.95

Lucira Health Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.0 Mil.

Lucira Health (OTCPK:LHDXQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lucira Health's Interest Expense for the three months ended in Sep. 2022 was $-0.9 Mil. Its Operating Income for the three months ended in Sep. 2022 was $-126.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was $45.8 Mil.

Lucira Health's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Lucira Health did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lucira Health (Lucira Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1412 62nd Street, Emeryville, CA, USA, 94608

Website

https://www.lucirahealth.com

Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.

Executives

Anthony Joseph Allen	officer: Chief Operations Officer	1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding	other: CEO of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc	10 percent owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps	other: Less than 10% Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah	officer: Ex. VP &Chief Quality Officer	1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins	officer: Chief Revenue Officer	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George	officer: CFO and Treasurer	1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson	director, officer: President and Chief Executive	1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra	director, officer: Chief Technology Officer	1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar	officer: Vice President	1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley	director	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608